Litcius/Paper detail

728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors

Omer Abdul Hamid, T. Sato, D. Davar, M.K. Callahan, F. Thistlethwaite, R. Aljumaily, M.L. Johnson, H-T. Arkenau, Ecaterina E. Dumbrava, B. Izar, H.A. Chen, S. Marshall, Y. Yuan, M. Deo, S. Stanhope, L. Collins, R. Mundy, Shaad E. Abdullah, J.S. Lopez

2022Annals of Oncology25 citationsDOI

Topics & Concepts

MedicineBispecific antibodyDe-escalationPhase (matter)Nuclear medicineCancer researchImmunologyInternal medicineAntibodyMonoclonal antibodyPhysicsQuantum mechanicsMonoclonal and Polyclonal Antibodies ResearchRadiopharmaceutical Chemistry and ApplicationsGlycosylation and Glycoproteins Research